Buy Candesartan

Candesartan

Candesartan: Heart & Blood Pressure Medication Overview

Candesartan, marketed in the United Kingdom as a pill containing the active ingredient candesartan cilexetil, belongs to the angiotensin II receptor blocker (ARB) class. It is available in strengths of 4 mg, 8 mg, and 16 mg and is prescribed by a qualified healthcare professional for the management of high blood pressure and certain forms of heart failure. The Medicines and Healthcare products Regulatory Agency (MHRA) classifies candesartan as a prescription-only medicine (POM).

How Candesartan Works in the Body

• Pro-drug conversion: Candesartan cilexetil is an inactive pro-drug that is rapidly absorbed from the gastrointestinal tract and converted by esterases into the active molecule candesartan.
• AT₁-receptor blockade: The active compound selectively blocks the angiotensin II type 1 (AT₁) receptors on blood vessels and the adrenal gland.
• Physiological effects: By preventing angiotensin II from binding to AT₁ receptors, candesartan reduces vasoconstriction, lowers aldosterone secretion, and diminishes sympathetic activation. The net result is reduced arterial resistance, lower blood pressure, and decreased workload on the heart.
• Onset and duration: Blood-pressure-lowering effects typically begin within 2 hours of the first dose, with a steady-state effect reached after about 2 weeks of daily dosing.

Conditions Treated by Candesartan

• Hypertension (high blood pressure): Approved for the long-term reduction of systolic and diastolic blood pressure in adult patients.
• Heart failure with reduced ejection fraction: Indicated as a component of optimal medical therapy to improve symptoms and reduce hospitalization.
• Diabetic nephropathy (UK guidance): Though not a formal indication, the MHRA acknowledges its use to slow the progression of kidney disease in patients with type 2 diabetes and albuminuria when combined with other antihypertensives.

Evidence-Based Off-Label Uses

• Hypertensive emergencies in pregnancy (first trimester): Candesartan is not approved for use during pregnancy because ARBs can cause fetal toxicity.
• Primary prevention of cardiovascular events: Some clinical trials have explored ARBs for reducing the risk of myocardial infarction and stroke, but current UK guidelines reserve candesartan for approved indications only.

Disclaimer: Off-label use of candesartan must be overseen by a qualified clinician who can assess individual risk-benefit balance.

Who Should and Should Not Use Candesartan?

Ideal Candidates

• Adults diagnosed with primary hypertension or stable chronic heart failure.
• Patients requiring an ARB after an ACE-inhibitor-induced cough.

Absolute Contraindications

• Known hypersensitivity to candesartan or any component of the tablet.
• Pregnancy (especially second and third trimesters) or breastfeeding.
• Severe hepatic impairment (Child-Pugh C).

Relative Contraindications & Precautions

• Moderate hepatic impairment (dose adjustment may be required).
• Elevated serum potassium (>5.0 mmol/L) or existing hyperkalaemia.
• Chronic kidney disease (creatinine clearance < 30 mL/min); monitor renal function closely.
• Concomitant use of dual RAAS blockade (e.g., ACE-inhibitor + ARB) - increased risk of renal dysfunction and hyperkalaemia.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Dizziness or light-headedness - often related to the blood-pressure-lowering effect.
• Headache - usually mild and transient.
• Fatigue or tiredness - may improve as blood pressure stabilises.
• Back pain - reported sporadically.

Serious Adverse Events

• Angio-edema - swelling of the face, lips, tongue, or throat; requires emergency medical attention.
• Severe hypotension - particularly after the first dose or when combined with other antihypertensives.
• Acute kidney injury - indicated by a sudden rise in serum creatinine; monitor renal function after initiation.

Major Drug Interactions

• Potassium-sparing diuretics (e.g., spironolactone) - increase the risk of hyperkalaemia.
• ACE inhibitors or other ARBs - dual blockade can precipitate renal insufficiency and marked hyperkalaemia.
• Non-steroidal anti-inflammatory drugs (NSAIDs) - may blunt the antihypertensive effect and raise renal risk.
• Lithium - candesartan can raise lithium concentrations; serum levels should be monitored.

Food and Lifestyle Interactions

• Food: Candesartan can be taken with or without meals; no specific dietary restrictions are required.
• Alcohol: Moderate intake is unlikely to affect efficacy, but excessive alcohol may worsen hypotension.
• Driving: Patients experiencing dizziness should avoid operating heavy machinery until they know how the medication affects them.

Note: Always inform your healthcare provider of all medicines, supplements, and herbal products you are using before starting candesartan.

How to Take Candesartan

• Standard dosing for hypertension:

• Start with 4 mg once daily.

• If additional blood-pressure control is needed, increase to 8 mg after 2-4 weeks.

• Maximum recommended dose for most adults is 16 mg once daily (higher doses are not listed in the UK product range).

• Heart failure dosing: Typically begins at 4 mg once daily; titration to 8 mg or 16 mg may follow clinical response and tolerability.

• Administration: Swallow the tablet whole with a full glass of water. Do not crush or chew.

• Missed dose: Take the missed tablet as soon as you remember unless it is close to the time of the next scheduled dose; do not double-dose.

• Overdose: Symptoms may include marked hypotension, dizziness, or fainting. Seek emergency care; supportive measures such as intravenous fluids and vasopressors may be required.

• Discontinuation: Do not stop abruptly if the medication is used for heart failure; a gradual taper under medical supervision helps avoid rebound hypertension.

Monitoring and Follow-Up

• Blood pressure: Check weekly until target levels (≤ 130/80 mmHg for most patients) are achieved, then at routine clinic visits.
• Renal function: Serum creatinine and estimated glomerular filtration rate (eGFR) should be measured within 1-2 weeks of initiation and after any dose increase.
• Serum potassium: Baseline potassium and repeat testing after dose changes, especially when combined with potassium-sparing agents.

Patients should contact their clinician promptly if they experience persistent dizziness, swelling of the face or lips, or a sudden rise in blood pressure.

Storage and Handling

• Keep tablets in the original blister pack until use.
• Store at room temperature (≤ 25 °C), protected from moisture and direct sunlight.
• Do not use the medication after the expiry date printed on the pack.
• Dispose of unused tablets safely, preferably via a pharmacy take-back scheme, to keep them out of reach of children.

Medication-Specific Glossary

Angiotensin II Receptor Blocker (ARB)

A class of drugs that inhibit the angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone release.

Pro-drug

An inactive compound (candesartan cilexetil) that is metabolised in the body to produce the active drug (candesartan).

Hyperkalaemia

Elevated potassium levels in the blood, which can affect heart rhythm; a known risk when using ARBs with potassium-sparers.

Angio-edema

Rapid swelling of deeper layers of the skin or mucosa, potentially compromising the airway; a serious, though rare, adverse reaction to ARBs.

eGFR (estimated Glomerular Filtration Rate)

A calculated measure of kidney function used to adjust dosing of renally excreted medicines.

Medical Disclaimer

This article provides educational information about candesartan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.